Who is Aegate?

Aegate was set up in 2004 to address growing concerns relating to patient safety, particularly counterfeit medicines. We have offices in a growing number of European countries, currently UK, Belgium, Greece, and Italy.

Aegate's major shareholder is Ipex Capital, an independent, venture capital company which was demerged from PA Consulting in 2008. Ipex Capital not only provides Aegate with independent funding but works closely with PA Consulting, providing us with access to PA's broad expertise and reach - something we continue to value highly.